News coverage about Clementia Pharmaceuticals (NASDAQ:CMTA) has trended somewhat negative on Friday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a news impact score of -0.05 on Accern’s scale. Accern also gave media headlines about the company an impact score of 48.3438166877132 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Clementia Pharmaceuticals (CMTA) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Clementia Pharmaceuticals (CMTA) Scheduled to Post Earnings on Wednesday (americanbankingnews.com)
- Clementia Pharmaceuticals (CMTA) Cut to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Brokers Offer Predictions for Clementia Pharmaceuticals’ FY2018 Earnings (CMTA) (americanbankingnews.com)
- Wedbush Research Analysts Lower Earnings Estimates for Clementia Pharmaceuticals (CMTA) (americanbankingnews.com)
Clementia Pharmaceuticals opened at $18.25 on Friday, MarketBeat Ratings reports. The company has a market cap of $578.54 million and a P/E ratio of -2.30. Clementia Pharmaceuticals has a 1 year low of $17.96 and a 1 year high of $18.25.
Clementia Pharmaceuticals (NASDAQ:CMTA) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.09). analysts anticipate that Clementia Pharmaceuticals will post -1.77 earnings per share for the current year.
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. ValuEngine raised shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, B. Riley assumed coverage on shares of Clementia Pharmaceuticals in a report on Wednesday, March 28th. They set a “buy” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $26.60.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.